Provided by Tiger Trade Technology Pte. Ltd.

NeuroPace Inc.

15.67
+0.18001.16%
Post-market: 15.670.00000.00%19:04 EST
Volume:123.24K
Turnover:1.93M
Market Cap:518.39M
PE:-20.81
High:15.98
Open:15.79
Low:15.31
Close:15.49
52wk High:18.98
52wk Low:7.56
Shares:33.08M
Float Shares:22.52M
Volume Ratio:0.59
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7530
EPS(LYR):-0.9318
ROE:-169.27%
ROA:-11.19%
PB:27.99
PE(LYR):-16.82

Loading ...

NeuroPace Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 27

NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M

TIPRANKS
·
Jan 13

NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M

TIPRANKS
·
Jan 13

Neuropace Projects Up to $100 Million Revenue in 2026 Outlook

Reuters
·
Jan 13

Neuropace Inc - Expects FY 2025 Revenue of $100 Mln, up 25%

THOMSON REUTERS
·
Jan 13

Neuropace Inc - Revenue for Q1 of 2026 Is Expected to Be Approximately $21 Mln to $22 Mln

THOMSON REUTERS
·
Jan 13

Neuropace Inc - Ends Distribution Agreement With Dixi Medical

THOMSON REUTERS
·
Jan 13

Neuropace Inc - Ige Expected Following Potential Approval in H2 2026

THOMSON REUTERS
·
Jan 13

Neuropace Inc FY2026 Shr View $-0.63, REV View $98.5 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 13

Neuropace Inc - Currently Anticipates 2026 Total Revenue of $98 Mln to $100 Mln

THOMSON REUTERS
·
Jan 13

Neuropace, Inc. Outlook FY Gross Margin 81-82%

THOMSON REUTERS
·
Jan 13

NeuroPace Submits FDA Application to Expand RNS System Indication for Drug-Resistant Epilepsy

Reuters
·
Dec 17, 2025

Neuropace Files Pma Supplement to FDA Seeking Expanded Rns® System Indication for Idiopathic Generalized Epilepsy

THOMSON REUTERS
·
Dec 17, 2025

UBS Adjusts NeuroPace Price Target to $22 From $18, Maintains Buy Rating

MT Newswires Live
·
Dec 16, 2025

NeuroPace Is Maintained at Buy by UBS

Dow Jones
·
Dec 16, 2025

NeuroPace Is Maintained at Overweight by JP Morgan

Dow Jones
·
Dec 11, 2025

Neuropace Inc - 77% Median Reduction in Gtc Seizures at 18 Months

THOMSON REUTERS
·
Dec 08, 2025

Neuropace: Remains on Track to Submit Nautilus Pma Supplement to FDA for Ige Indication Expansion by Year-End

THOMSON REUTERS
·
Dec 08, 2025

Neuropace Announces Positive 18-Month Nautilus Trial Results in Idiopathic Generalized Epilepsy

THOMSON REUTERS
·
Dec 08, 2025

NeuroPace Reports Positive 18-Month Results from NAUTILUS Trial for Drug-Resistant Epilepsy

Reuters
·
Dec 08, 2025